BioXcel Therapeutics Q3 2024 net loss narrows to $13.7M; advances Phase 3 trials for agitation

BioXcel Therapeutics, Inc.

2024-Q3 EPS reported -$1.29 revenue$1,900,000

Net loss of $13.7M in Q3 2024 vs $50.5M loss in Q3 2023; operating cash use $16.3M.
IGALMI net revenue $214k in Q3, down from $341k YoY; nine-month revenue $1.9M, up 89%.
R&D expenses $5.1M vs $19.6M; SG&A $7.7M vs $24.3M, both lower due to restructuring.
First patient randomized in SERENITY At-Home Phase 3 trial for bipolar/schizophrenia agitation; 9-12 month duration.
Cash and equivalents $40.4M as of Sept 30, 2024; patent portfolio extended to 2043.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.